BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer's Disease Program


6/29/2012 10:46:39 AM

Kraków, Poland, and Espoo, Finland, June 29, 2012 / B3C newswire / - Selvita S.A., a biotechnology company from Krakow, Poland (PL:SLV) announced today that its collaboration with Orion Corporation from Espoo, Finland (ORNBV) on SEL103 program, for the symptomatic treatment of Alzheimer’s disease has reached the main research milestone and that the jointly discovered molecules from two different chemical families will progress into further pre-clinical characterization before the selection of a candidate into development.

The companies entered into a global collaboration with the aim to discover, develop and commercialize SEL103, Selvita’s proprietary program for the treatment of Alzheimer’s disease and other cognitive disorders in 2010. Selvita is responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

Under the terms of the agreement, Selvita is responsible for the discovery and Orion is responsible for the development and global commercialization.

“The joint project with Orion and Selvita has been proceeding very well despite of many challenges in the biology. I have enjoyed working with the open minded, enthusiastic, and goal-oriented team of Selvita that has been able to meet the pre-agreed deliverables of the project. Especially, Selvita’s medicinal chemistry design and synthesis people have even exceeded the high expectations we had in the start. While practical work is now gradually switching from Selvita to Orion’s responsibility I look forward to seeing confirmatory preclinical study results that would qualify compound(s) to be selected for further development and clinical studies” said Dr. Jukka Sallinen, Head of CNS Research of Orion. “We are delighted with the research progress in SEL103" said Pawel Przewiezlikowski, the Chief Executive Officer of Selvita, "The milestone with Orion is the first publicly announced milestone from Selvita integrated research collaborations and another proof of the skills of Selvita scientific team. We look forward to the further development of the program by Orion”.

About ALZHEIMER’S

Alzheimer's disease is the most common cause of dementia. Dementia is a collective name for progressive degenerative brain syndromes which affect memory, thinking, behavior and emotion. Although there are no drugs that can cure Alzheimer's disease, there are some treatments that can help people with Alzheimer's disease. However, better drug treatments are needed, especially due to the aging of human population. Currently there are an estimated 30 million people worldwide with dementia. Two thirds of them live in developing countries. This figure is set to increase to more than 100 million people by 2050. Much of this increase will be in rapidly developing and heavily populated regions such as China, India and Latin America (according to Alzheimer’s Disease International, ADI).

About SEL103

Selvita’s SEL103 program is based on novel, orally bioavailable and highly selective small-molecules which have the potential to play role in the treatment of multiple cognitive disorders, including Alzheimer’s disease, dementias, etc. About SELVITA

SELVITA is a Polish, biotechnology company listed on the Warsaw Stock Exchange (PL:SLV) engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders as well as provision of non-clinical research services. It was established and 2007 and currently employs 140 scientists, including 50 PhDs. SELVITA has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2012. The most advanced programs at Selvita are SEL103 for the symptomatic treatment of Alzheimer’s disease, SEL141 - a discovery stage program targeting tau-hyperphosphorylation through DYRK1A kinase, as well as SEL24 (PIM) and SEL120 (CDK8/9) kinase inhibitor programs in oncology.

About ORION

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

Contacts:

Natalia Baranowska

Selvita S.A.

ul. Bobrzynskiego 14,

30-348 Krakow

Poland

tel.: +48 12 297 47 00

fax +48 12 297 47 01

natalia.baranowska@selvita.com

Dr. Antti Haapalinna

Orion

VP, Research, Pharmaceutical R&D

antti.haapalinna@orionpharma.com

SELVITA Forward-looking Statement

This press release contains "forward-looking statements," including statements related to the potential value of payments, which may be received pursuant to our collaboration with ORION and the anticipated development of SEL103 pursuant to the collaboration in CNS disorders, and the future responsibilities of the parties under the collaboration agreements. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the conduct and results of pre-clinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market products resulting from our development efforts, our reliance on partners, including Orion, and other key parties for the successful development, manufacturing and commercialization of products, the adequacy of our capital resources and the availability of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceedings concerning our patent portfolio, future capital needs, key employees, markets, economic conditions, prices, reimbursement rates, competition and other factors The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES